 Acquisition establishes NeoGenomics as a technology leader in the minimal residual disease MRD testing market FT. MYERS, FL ACCESSWIRE June 18, 2021 NeoGenomics, Inc. NASDAQ:NEO, a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has completed its acquisition of Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England. 